1.8 - 2.04
1.67 - 23.53
Join Discuss about HGEN with like-minded investors
$HGEN a few months ago the CSO Bought 1 million shares @$3 and a whole bunch of May 20th Calls. The reason was upcoming data from NIH study of therir drug as a therapeutic for CV19. This morning the CEO postsed a tweet saying the market position would be known after memorial day. Boom all the people who had bought the May20 calls are in an unenviable position looking at a total lose.... so they start to sell, however the market makers are hedged against all those positions so they need to get out of the position....boom market up and HGEN under pressure... but nothing has changed just forced selling by Market makers
40 Replies 7 👍 9 🔥
a LITTLE PIECE OS sHIT I HAVE A HOLDING IN IS UP 15% TODAY..... $HGEn..... it is a carT DRUG DEVELOPER WITH a drug which is being assessed for CV19 ... supposedly it works at cutting down cytokine storms.... results are due soon... the CSO has 20th may options he bought a few months ago ..... dangerous ground but i would think the upside is much bigger than the downside here
149 Replies 8 👍 15 🔥
Lenzilumab is the drug $HGEN are currently in phase 3 trials for . Results in next month or so, maybe less. The drug stops these cytokine storms which kill folks. Anyway i mentioned on here before insider buying and Onr exec buying 1 mill shares worth $3 mill. ANYWAY IT IS SELLING OFF AND LOOKS LIKE IT MAY GO SUB $3 test the 20 dma. The company probably needs to raise cash at somepoint, however current valuation if used in endemic treatment of Covid is for a $1 billion revenue .... which points to an eventual value of the stock of $90 ..... but wait theres more ...... the company has been talking to researchers and the drugs looks like a good fit for treating long covid ..... if that works out it could be worth $$$$. Anyways for gamblers it looks a decent bet on upcoming news
53 Replies 14 👍 8 🔥
@lucullus thanks for dropping HGEN, I'm up nicely on it.
83 Replies 7 👍 13 🔥
$HGEN had some unusual option activity a weeks or so ago, may calls well OTM AT $5 AND $7 when trading around $2.50. Turns out the calls were bought by Dale Chappell who happens to be the CSO at the company, they have phase 3 results due soon on a drug which handles cytokine storms
57 Replies 7 👍 6 🔥
IU Watchlist for Sept 10: $ATER chart doesn't work but I'd love to see this push up $10.50s + again before $8s $RKLB had big plans on this thing but damn did it stay super strong - got short this AM got a great fade nearly $2 fade - started to grind and held EVERY key level given so rather than add add add I waited as I said wait wait wait and then leaned in when I noted EOD. Nice flush EOD before coming back. I'd love to see $2-3 on air fade off and then head red $2-3/share. I think there can be a HUGE trade here but here's the thing step in front, heavy conviction, over size and get smoked. BE CAUTIOUS. Wait for the trade. Wait for things to fail. $GEVO nice idea today on long side. Scalped it short a few times. Either this has a so so open and fades off or we have a huge $8.20-8.50 + blow off move like MMAT day and then unwind. Ready and waiting. $AMC feel like this may have an opportunity after they burn some call sellers early. Failed Follow Through: $CEI ideally huge gap $1.50-1.70+ then fade off. Great alert on the PR today I got net long sub $1 took the 20% move ended up net short and then said to myself why bother trying to figure out this box my entire goal of the box was b/c it was near a buck and I wanted it in Etrade - it's well over a buck now so not worried about getting the borrow there anymore. $HGEN blow off open then 945-10AM + failed follow through I'd look to trade. $ENVB $3.40s still area of interest.
51 Replies 13 👍 10 🔥
@DarkPoolAlgo #Dark Pool Charts
Thursday, September 9, 2021 Following a day of weakness, U.S. stock futures are again looking modestly lower, pulling back along with declines in both Europe and Asia as the spread of the delta strain of Covid-19 continues to weigh on the U.S. economy. This morning, two airlines noted impact to revenues due to a decline in travel. Tech stocks in China fell after regulators again increased pressure on gaming companies for focusing solely on profit. In Asian markets, The Nikkei Index declines -173 points to hold just above 30K, the Shanghai Index rose 17 points to 3,693 and the Hang Seng Index dropped over -600 points (2.3%) to settle at 25,716. In Europe, the German DAX is down about -40points to 15,570, while the FTSE 100 tumbles over -80 points (1.2%) to hold around the 7,000 level. Yesterday, Europe’s Stoxx 600 was down 1.0%, marks worst day in nearly 3 weeks as the German Dax down 1.4%, marks worst day since mid-July. Later this morning, we get the European Central Bank (ECB) rate decision at 7:45 AM and press conference at 8:30 AM where investors will look for clues about inflation and or asset tapering. The S&P 500 Index was lower for a third straight session Wednesday amid increasing concerns about economic growth and the ongoing spread of Covid. The Federal Reserve’s Beige Book report showed that economic growth downshifted slightly to a moderate pace from early July through August, largely due to a pullback in dining out, travel and tourism because of consumers’ safety fears. The dollar pared earlier gains, while Treasuries recovered Tuesday’s losses. Market Closing Prices Yesterday · The S&P 500 Index slipped -5.96 points, or 0.13%, to 4,514.07 · The Dow Jones Industrial Average fell -68.93 points, or 0.20%, to 35,031.07 · The Nasdaq Composite dropped -87.69 points, or 0.57%, to 15,286.64 · The Russell 2000 Index declined -25.88 points, or 1.14% to 2,249.73 Events Calendar for Today · 8:30 AM ET Weekly Jobless Claims · 8:30 AM EST Continuing Claims · 10:30 AM ET Weekly EIA Natural Gas Inventory Data · 11:00 AM ET Weekly DOE Inventory Data Earnings Calendar: · Earnings Before the Open: ASO, HOFT, HOV, JILL, LOVE, TUESQ · Earnings After the Close: AFRM, AMRK, AOUT, COOK, CXM, FARM, KLXE, LAKE, PLAY, PWSC, SUMO, VRNT, ZS, ZUMZ Other Key Events: · Barclay’s Global Consumer Staples Conference (virtual) 2021, 9/8-9/10 · Barclay’s CEO Energy-Power Conference 2021 (virtual), 9/8-9/10 · BTIG Cloud Communications and Collaboration Investor Forum (virtual), 9/8 · Citigroup Annual BioPharma Conference (virtual), 9/8-9/10 · Citigroup GEMS Conference 2021 (virtual), 9/8-9/10 · Cowen 14th Annual Global Transportation & Sustainable Mobility Conference, 9/8-9/10 · Credit Suisse 2021 Global Steel & Mining Conference (virtual), 9/8-9/10 · Stephens Building Materials Investor Trip, 9/8-9/9 · Wolfe Inaugural TMT Conference, 9/8-9/9 · Barrington Annual Fall Investment Conference (virtual), 9/9 · DA Davidson Annual Software & Internet Conference (virtual), 9/9 · Deutsche Bank 2021 Technology Conference (virtual), 9/9-9/10 · Goldman Sachs 11th Annual Financial Technology Conference (virtual), 9/9 · Needham 1st Annual Needham Crypto Conference (virtual), 9/9 · Wells Fargo 2021 Healthcare Conference (virtual), 9/9-9/10 Sector News Breakdown Consumer · Lululemon ($LULU) shares rise 10%; 2Q adj EPS $1.65 vs est. $1.19 on revs $1.5B vs est. $1.33B; guides 3Q adj EPS $1.33-1.38 vs est. $1.32, sees 3Q revs $1.4-1.43B vs est. $1.32B; guides FY adj EPS $7.38-7.48 vs est. $6.91; raises year revs to range of $6.19B-$6.26B, compared with its prior range of $5.83B-$5.91B · RH Corp. ($RH) 2Q adj EPS $8.48 vs est. $6.48 on revs $989Mm vs est. $975.5Mm; guides FY revs +31-33% up from prior 25%-30% view and vs est. +29.2% and op margin 24.9-25.5% , sees ROIC 70% vs prior 60%; says currently expecting manufacturing to restart in Vietnam in October with full capacity by end of year · Boston Beer Company Inc ($SAM) shares fell -8%; said since last guidance update market for hard seltzer products has continued to experience decelerating growth trends; believe there will be continuing uncertainty about hard seltzer demand trends for remainder of 2021; said it is withdrawing its 2021 financial guidance issued on July 22, 2021 as EPS will fall below previously-reported estimate of between $18.00-$22.00 · Caesars ($CZR) announced an agreement to sell the non-US assets of William Hill to 888 Holdings for approximately GBP 2.2B · Copart (C$PRT) Q4 non-GAAP EPS $1.03 vs. est. $0.91; Q4 revs $748.6M vs. est. $690.87M · VICI Properties ($VICI) announces offering of 100M shares of common stock · GameStop ($GME) Q2 EPS loss (-$0.76) vs. est. loss (-$0.67); Q2 revs $1.183B vs. est. $1.12B; Ended the period with cash and restricted cash of $1.78B · Calavo Growers ($CVGW) 3Q adj EPS ($0.17) vs est. ($0.05) on revs $285Mm vs est. $281.7Mm · Limoneira ($LMNR) Q3 adj EPS $0.20 vs. est. $0.18; Q3 revs $49.1M vs. est. $48.8M; Agribusiness revenue Q3 includes $24.4M in fresh lemon sales, compared to $35.4M of fresh lemon sales during the same period of fiscal year 2020; approximately 1,144,000 cartons of fresh lemons were sold in aggregate · Torrid ($CURV) 2Q adj EPS $0.36 vs est. $0.16 on sales $332.9Mm vs est. $294.7Mm; guides 3Q sales $305-315Mm vs est. $305.1Mm; guides FY sales $1.29-1.31B vs est. $1.3B Energy, Industrials and Materials · The American Petroleum Institute ($API) reports that crude inventories fell 2.88M barrels last week and gasoline inventories fell 6.41M barrels · United Airlines ($UAL) said it expects third-quarter capacity to fall at least 28% compared with the same period in 2019, as bookings take a hit due to the rise in COVID-19 cases fueled by the Delta variant. · Southwest Airlines ($LUV) said it sees October operating revenue down 20% to 30% vs 2019; expects q4 2021 capacity to increase about 60% YoY and to decrease about 5% vs. Q4 2019 · Sherwin-Williams ($SHW), Axalta Coating (AXTA), and PPG Industries (PPG) all downgraded to Neutral from Buy at Citigroup · ABM Industries ($ABM) Q3 revenue $1.54B vs. est. $1.51B; Q3 EPS from continuing operations $0.90 vs. est. $0.81; sees FY adj eps cont ops $3.45 to $3.55, vs. prior view $3.30 to $3.50 · AeroVironment ($AVAV) Q1 adj EPS loss (-$0.17) vs. est. loss (-$0.24); Q1 revs $101M vs. est. $96.48M; backs FY22 adj EPS view $2.50-$2.70 (est. $2.64) and backs FY22 revenue view $560M-$580M (est. $569.34M) Financials · Digital Realty ($DLR) 6.25M share Spot Secondary priced at $160.50 · Riot Blockchain ($RIOT) produces 441 Bitcoins in August, down from the 444 BTC produced in July; on a Y/Y basis, its production increased 451% from 80 BTC in August 2020. Healthcare · Humanigen ($HGEN) plunges over 50% after U.S. FDA declines emergency use approval for COVID-19 drug; said the FDA declined to grant emergency use authorization for its drug, lenzilumab, to treat patients hospitalized with COVID-19 · ProQR Therapeutics ($PRQR) announces a global licensing and research collaboration with Eli Lilly (LLY) to discover new medicines for genetic disorders in the liver and nervous system, in a deal that could be worth over $1.25B · Avid Biosciences ($CDMO) Q1 EPS $0.10 vs. est. $0.04; Q1 revs $30.8M vs. est. $27.8M; · HealthEquity Corp. ($HQY) 2Q adj EPS $0.40 vs est. $0.36 on revs $189.1Mm vs est. $184.7Mm; guides FY adj EPS $1.45-1.50 vs est. $1.49, sees FY revs $755-765Mm vs est. $762.8Mm; says re: WageWorks have achieved approximately $70 million of the approximately $80 million in annualized ongoing net synergies we expect to achieve by the end of fiscal year 2022. · Cardiff Oncology ($CRDF) updated data from its Phase 1b/2 clinical trial for onvansertib in combination with standard-of-care (SOC) as second-line therapy in patients with KRAS-mutated metastatic colorectal cancer (mCRC); said as of data cut off July 2, 2021, eight of 19 (42%) patients who received the recommended Phase 2 dose of onvansertib 15 mg/m2 and were evaluable for disease response achieved a partial response · Turning Point Therapeutics ($TPTX) announces early clinical data for Repotrectinib in NTRK fusion-positive advanced solid tumors selected for late-breaker plenary presentation at 2021 AACR-NCI-EORTC conference · Beauty Health ($SKIN) announces $400M convertible senior notes offering Technology, Media & Telecom · Cisco ($CSCO) downgraded to Equal Weight from Overweight at Morgan Stanley · NetEase ($NTES) and Tencent (TCEHY) tumble again as China’s focus on reining in the power of tech companies hasn’t abated. A report in the South China Morning Post notes that the government will halt approvals for new online games. · Sea Limited ($SE) is looking to sell 11 million ADRs with the option to offer 1.65 million more as part of a so-called green shoe option; it is also raising $2.5 billion in a convertible bond that has a $375 million green shoe attached · SentinelOne ($S) Q2 revenue $45.8M vs. est. $40.4M; Q2 ARR up 127% YoY; total customer count grew more than 75% year-over-year to over 5,400 customers as of July 31; Customers with ARR over $100K grew 140% year-over-year to over 345 as of July 31, 2021; guides year revs $188M-$190M vs. est. $176.4M
107 Replies 10 👍 15 🔥
Upside: -ENOB +159% (announces FDA Acceptance of Pre-IND Request for Potential HIV Cure) -ITOS +51% (GSK and iTeos announce development and commercialisation collaboration for EOS-448) -CRSR +15% (hearing interest from WallStreetBets) -NVAX +9.0% (COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial) -LPCN +8.3% (FDA clears LPCN 1154 IND application for a Phase 2 Postpartum Depression Study) -RIOT +8.3% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -HAPP +7.8% (signed agreement to distribute Volkswagen Electric Vehicles) -MARA +7.8% (crypto strength following TSLA CEO Musk indicating car maker may resume BTC transactions) -RAPT +7.7% (reports positive topline results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis) -AMTX +6.0% (signs $200M biofuels offtake agreement with international renewable fuels supplier Murex, LLC to be delivered during 2021 to 2023) -OCC +5.4% (earnings) -EFOI +4.8% (enters marketing partnership with FirstEnergy Home and FirstEnergy Advisors) -TWST +3.2% (collaborates with Regeneron for production of genotyping by sequencing panel to enable diverse genome-wide screening) -HGEN +2.8% (initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)) -CODA +2.3% (earnings) -OTLK +2.3% (announces inclusion in the Russell 2000 Index, effective June 25, 2021) -SVOK +1.1% (confirms Boxed to go public through merger with Seven Oaks Acquisition Corp. in deal valued at ~$900M) Downside: -ATXI -47% (receives Complete Response Letter from the FDA for IV Tramadol, saying it does not support benefits as a monotherapy) -RIDE -11% (CEO and CFO resign following results of special committee investigation of Hindenburg Research report) -HEXO -3.6% (earnings) -NKLA -1.5% (discloses entered into a purchase agreement and a registration rights agreement with Tumim Stone Capital to sell $300M of the Nikola's common stock)
43 Replies 14 👍 14 🔥
quick win in HGEN for a double
110 Replies 11 👍 9 🔥
sun check out HGEN daily
128 Replies 7 👍 15 🔥
👀 are on HGEN as well. No volume yet.
44 Replies 14 👍 6 🔥
Next Dividend Date
Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.
CEO: Cameron Durrant
HQ: 533 Airport Blvd Ste 400 Burlingame, 94010-2013 California